Gyg Investors - GYG

Gyg Investors - GYG

Trade Now

Capital at risk Advertisement
Stock Name Stock Symbol Market Stock Type
Gyg Plc GYG London Ordinary Share
  Price Change Price Change % Stock Price Last Trade
-1.00 -4.0% 24.00 08:45:37
Open Price Low Price High Price Close Price Previous Close
25.00 24.00 25.00 25.00
more quote information »
Industry Sector
INDUSTRIAL TRANSPORTATION

Top Investor Posts

DateSubject
09/4/2021
16:49
dubai123: Will certainly be attending the investor presentation on investor meet company next week.
07/5/2019
08:55
shiv1986: ADVFN is hosting an investor event for a firm within Industrial Transportation; Avation plc, on the 21st May to find out about their future prospects. Sign up to attend this event: https://uk.advfn.com/stock-market/london/advfn-AFN/share-news/ADVFN-PLC-ADVFN-Investor-Event-for-Avation-plc/79847603
16/7/2018
16:11
jonwig: He's a gambler (and with others' money) not a investor! @ cambridgedon - clear your cache and cookies then try again.
18/4/2018
08:54
its the oxman: Can see this running back to 150p come next set of results, outlook all looks good , investor meetings should go well, and taps into the trend of the super rich getting richer which is only going to continue.
05/4/2018
17:54
mrnumpty: jonwig . Thanks for your comments and your diligence - I couldn't find any information on the Company's website regarding the increased holding by Woodford , but Interactive Investor shows that he has increased his holding from 18.20% to 19.34% .
05/4/2018
08:35
mrnumpty: I'm as demoralised as anyone else by the drop in the share price , and I have learnt to respect the comments made by " jonwig " , both here and on other sites( e.g. Burford Capital plc ) . However , according to the Hargreaves Lansdown site , there were four decent purchases yesterday ( 4/4/2018 ) , totalling 225,000 shares for £ 239,775 ( 11.08am 20,000 @ £ 1.05 ; 11.45am 50,000 @ £ 1.07 ; 12.12am 40,000 @ £ 1.07 ; 16.14 115,000 @ £ 1.06.5 ) . I am certainly aware that the figures on the Hargreaves site need to be looked at sceptically , as " buys " and " sells " are often reported wrongly . However , if this information is correct , then , given that the Market Cap is only £ 48.51 M , and that 82.82% of the shares are held by institutions or directors ( source : the company's " investors " section of its website ) , then these four purchases constitute a decent percentage of the Mkt Cap ( 0.49 % ) , or , more impressively , over 2.8% of the free float ( 17.18% not held by institutions or directors ) . Could this be a case of " very clever institutions " benefitting from the abrupt fall in the share price ? Only time will tell , but only a couple of weeks until the RNS . Do your own research .
18/1/2018
08:58
robinnicolson: hxxp://www.superyachtnews.com/business/the-billionaires-and-millionaires-markets “Many of the investors that we sat down with, we had to convince them that we were not in the 25m market, the millionaires market, we had to convince them that we are operating in the billionaires’ market…[and] that it was a legitimate industry that they could invest in"
30/9/2017
13:21
mrnumpty: jonwig , I have just looked at this bulletin board for the first time , as I am considering buying in to GYG ( tipped of course by Simon Thompson of the Investors' Chronicle ) . Your user name is well known to me , as I have been invested in Burford Capital for over two years , and you are a very regular and informative poster on the Burford Capital ADFN bulletin board . Are you invested in GYG ? Any inference made by me is entirely at my own risk . Good lick to all .
25/5/2007
14:59
maddox: In answer to the question 'whats' new with Gyrus - why the re-rating and up-graded forecasts?' The clue in the JP Morgan news is the reference to General Surgery. OK, we have discussed this before on the BB but lets do a reprise for anyone attracted by the price rise. Keyhole Surgery was until quite recently regarded as a specialism applicable to specific areas of surgery. Gyrus, for example, was seen as focussed on Gynaecology, ENT and sports injuries. Thus the market opportunity was viewed as similarly contained. However, the key point for investors that JPM is highlighting is the current growth in the use of keyhole techniques for almost all surgical procedures, with very few exceptions. More surgeons are adopting keyhole surgery, more types of operations are available and the increase in patient throughput possible is contributing to a far larger market opportunity. In short the keyhole surgery market is becoming the general surgery market. If you wish to have some independent validation of this trend have a look and listen to BBC Radio 4 'Case Notes' on Laproscopic (Keyhole) Surgery. Link: http://www.bbc.co.uk/radio4/science/casenotes_20060516.shtml - transcript available It also illustrates the benefits for hospitals and patients of keyhole surgery. Patients are having complex surgery and can be in and out the same afternoon. It is now typical for operations that could have required as much as a seven day stay in hospital such as for gall bladder removal. The operations are quicker and safer, there is less post-operative pain and the surgical results are better. These excellent results are not just applicable in the specialist areas where the techniques were pioneered but to almost all the general surgical market. Firms such as Gyrus are thus extremely well placed to follow this trend and do very well out of it. Their products such as PK Seal are remarkable in what they can do - why not have a look http://www.gyrusmedical.com/products_video.asp Regards, Maddox
23/3/2007
10:14
maddox: Investors Chronicle view on results - a few snippets: 'Once again, Gyrus has taken on the dollar and won. Trading at the surgical devices manufacturer was hit by currency fluctuations, but it still managed a robust performance, with operating profits up 84 per cent, year on year, to £19.1m, boosted by the acquisition of ACMI in 2005. Gross margins improved to 59.3 per cent from 55.6 per cent last year.' 'Executive chairman Brian Steer says the integration is going well and that Gyrus is "over the major hurdles". Indeed, with the exception of the flat sales at the ear, nose and throat division, revenue growth was strong. Sales in the surgical division grew 40 per cent in the period, to £52.5m, thanks to the buoyant US laparoscopic hysterectomy market. The roll-out of the PlasmaCision products into general surgery is also going well and should benefit the results this year. There is no word yet on who will take over from Mr Steer, who retires at the end of 2007, although he says there should be an update at the half-year results. Broker Numis Securities expects adjusted pre-tax profits of £40.4m for 2007 (£27.5m in 2006), with EPS of 20.6p (17.1p in 2006), rising to 25.5p in 2008.' 'The shares have had a strong run and trade on a pricey 21 times 2007's expected earnings, falling to 17 times for 2008. But, with excellent growth prospects ahead, expect more upside. Long-term good value.'
ADVFN Advertorial
Your Recent History
LSE
GYG
Gyg
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220816 09:32:46